Background: Diclofenac sodium (DS) and celecoxib (CEL) are primary anti-inflammatory agents used in the treatment of osteoarthritis (OA). Formulating these drugs into extended-release versions can effectively address the issue of multiple daily doses. In this study, we designed and synthesized a novel poly(lactic-co-glycolic acid) (PLGA) nanoliposome as a dual-drug delivery sustained-release formulation (PPLs-DS-CEL) to achieve long-lasting synergistic treatment of OA with both DS and CEL. Methods: PPLs-DS-CEL was synthesized by the reverse evaporation method and evaluated for its physicochemical properties, encapsulation efficiency, drug release kinetics and biological properties. A rat OA model was established to assess the therapeutic efficacy and biosafety of PPLs-DS-CEL. Results: The particle size of PPLs-DS-CEL was 218.36 ± 6.27 nm, with a potential of 32.56 ± 3.28 mv, indicating a homogeneous vesicle size. The encapsulation of DS and CEL by PPLs-DS-CEL was 95.18 ± 4.43% and 93.63 ± 5.11%, with drug loading of 9.56 ± 0.32% and 9.68 ± 0.34%, respectively. PPLs-DS-CEL exhibited low cytotoxicity and hemolysis, and was able to achieve long-lasting synergistic analgesic and anti-inflammatory therapeutic effects in OA through slow release of DS and CEL, demonstrating good biosafety properties. Conclusion: This study developed a novel sustained-release nanoliposomes formulation capable of co-loading two drugs for the long-acting synergistic treatment of OA. It offers a new and effective therapeutic strategy for OA treatment in the clinic settings and presents a promising approach for drug delivery systems.
YaoQWuXTaoC, et al.Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct Targeted Ther2023; 8(1): 56.
2.
KnightsAJReddingSJMaerzT. Inflammation in osteoarthritis: the latest progress and ongoing challenges. Curr Opin Rheumatol2023; 35(2): 128–134.
3.
LuHWeiJLiuK, et al.Radical-scavenging and subchondral bone-regenerating nanomedicine for osteoarthritis treatment. ACS Nano2023; 17(6): 6131–6146.
4.
Tuncay DuruözMÖzNGürsoyDE, et al.Clinical aspects and outcomes in osteoarthritis. Best Pract Res Clin Rheumatol2023; 37(2): 101855.
5.
EmamiANamdariHParvizpourF, et al.Challenges in osteoarthritis treatment. Tissue Cell2023; 80: 101992.
6.
HuangHLiangYHanD, et al.Case report: electroacupuncture for acute pain flare-up of knee osteoarthritis. Front Neurol2022; 13: 1026441.
7.
SwanJTRizkEDuongPY, et al.Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting. BMC Muscoskel Disord2023; 24(1): 761.
8.
LiDHangRMengL, et al.Co-Treatment with oral duloxetine and intraarticular injection of corticosteroid plus hyaluronic acid reduces pain in the treatment of knee osteoarthritis. Pain Physician2024; 27(1): E45–E53.
9.
SunZGuXHaoT, et al.Intra-articular injection PLGA blends sustained-release microspheres loaded with meloxicam: preparation, optimization, evaluation in vitro and in vivo. Drug Deliv2022; 29(1): 3317–3327.
10.
SethiVQinLCoxE, et al.Model-Based meta-analysis supporting the combination of acetaminophen and topical diclofenac in acute pain: a therapy for mild-to-moderate osteoarthritis pain?Pain Ther2024; 13(1): 145–159.
11.
SethiVQinLTrocónizIF, et al.Model-Based assessment of the liver safety profile of acetaminophen to support its combination use with topical diclofenac in mild-to-moderate osteoarthritis pain. Pain Ther2024; 13(1): 127–143.
12.
ChouTC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res2010; 70(2): 440–446.
13.
AhmedNLyHPanA, et al.Retrospective analysis of the biopharmaceutics characteristics of solid oral Modified-Release drug products in approved US FDA NDAs designated as Extended-Release or Delayed-Release formulations. Eur J Pharm Biopharm2023; 193: 294–305.
14.
HuangHLouZZhengS, et al.Intra-articular drug delivery systems for osteoarthritis therapy: shifting from sustained release to enhancing penetration into cartilage. Drug Deliv2022; 29(1): 767–791.
15.
HuangHPanJYangW, et al.Celecoxib vs diclofenac sodium in patients with knee osteoarthritis: a protocol for systematic review and meta analysis. Medicine (Baltim)2020; 99(15): e19680.
16.
HuangHLuoMLiangH, et al.Meta-analysis comparing celecoxib with diclofenac sodium in patients with knee osteoarthritis. Pain Med2021; 22(2): 352–362.
17.
WangWYuSLongZ, et al.Electroacupuncture vs topical diclofenac sodium gel for patients with hand osteoarthritis: study protocol for a randomized controlled trial. J Orthop Surg Res2022; 17(1): 233.
18.
ToluSKöseMMKorkmazMC, et al.Comparison of the efficacy of different concentrations of diclofenac sodium phonophoresis (1.16% vs 2.32%) in patients with knee osteoarthritis: a randomized double-blind controlled trial. Acta Chir Orthop Traumatol Cech2021; 88(2): 117–123.
19.
WangQYangXGuX, et al.Celecoxib nanocrystal-loaded dissolving microneedles with highly efficient for osteoarthritis treatment. Int J Pharm2022; 625: 122108.
20.
SharmaRYadavSYadavV, et al.Recent advances in lipid-based long-acting injectable depot formulations. Adv Drug Deliv Rev2023; 199: 114901.
21.
ChaurasiyaAGorajiyaAPanchalK, et al.A review on multivesicular liposomes for pharmaceutical applications: preparation, characterization, and translational challenges. Drug Deliv Transl Res2022; 12(7): 1569–1587.
22.
ObayemiJDJusuSMSalifuAA, et al.Degradable porous drug-loaded polymer scaffolds for localized cancer drug delivery and breast cell/tissue growth. Mater Sci Eng C2020; 112: 110794.
23.
LiuZChenXChenP, et al.Transcranial direct current stimulation attenuates the chronic pain of osteoarthritis in rats via reducing NMDAR2B expressions in the spinal cord. J Musculoskelet Neuronal Interact2023; 23(4): 498–505.
24.
HabibYHShetaEKhattabM, et al.Diminazene aceturate or losartan ameliorates the functional, radiological and histopathological alterations in knee osteoarthritis rodent model: repurposing of the ACE2/Ang1-7/MasR cascade. J Exp Orthop2023; 10(1): 107.
25.
WangJDongFFLiXF, et al.[Effects of Yiqi Huayu prescription on knee cartilage degeneration in HIF-1alpha gene knockout mice]. Zhong Guo Gu Shang2013; 26(6): 486–492.
26.
LimJHKimSEKimHJ, et al. Intra-articular injection of stigmasterol-loaded nanoparticles reduce pain and inhibit the inflammation and joint destruction in osteoarthritis rat model: a pilot study. Drug Deliv Transl Res. 2024. doi:10.1007/s13346-023-01501-w
27.
ZhangKYuJLiJ, et al.The combined intraosseous administration of orthobiologics outperformed isolated intra-articular injections in alleviating pain and cartilage degeneration in a rat model of MIA-induced knee osteoarthritis. Am J Sports Med2024; 52(1): 140–154.
28.
ZhongYZhouYDingR, et al.Intra-articular treatment of temporomandibular joint osteoarthritis by injecting actively-loaded meloxicam liposomes with dual-functions of anti-inflammation and lubrication. Mater Today Bio2023; 19: 100573.
29.
FouadSAMalaakFAEl-NabarawiMA, et al.Development of orally disintegrating tablets containing solid dispersion of a poorly soluble drug for enhanced dissolution: in-vitro optimization/in-vivo evaluation. PLoS One2020; 15(12): e0244646.
30.
WangGZhangXAKapilevichL, et al.Recent advances in polymeric microparticle-based drug delivery systems for knee osteoarthritis treatment. Front Bioeng Biotechnol2023; 11: 1290870.
31.
DwivediSDYadavKBhoiA, et al.Targeting pathways and integrated approaches to treat rheumatoid arthritis. Crit Rev Ther Drug Carrier Syst2024; 41(4): 87–102.
32.
JiangYLiWWangZ, et al.Lipid-Based nanotechnology: liposome. Pharmaceutics2023; 16(1): 34.
33.
AndersonRFranchACastellM, et al.Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis. Arthritis Res Ther2010; 12(4): R147.
34.
LinWKampfNGoldbergR, et al.Poly-phosphocholinated liposomes form stable superlubrication vectors. Langmuir2019; 35(18): 6048–6054.
35.
PawarVAManjappaASMurumkarPR, et al.Drug-fortified liposomes as carriers for sustained release of NSAIDs: the concept and its validation in the animal model for the treatment of arthritis. Eur J Pharmaceut Sci2018; 125: 11–22.
36.
ChenCHKuoSMTienYC, et al.Steady augmentation of anti-osteoarthritic actions of rapamycin by liposome-encapsulation in collaboration with low-intensity pulsed ultrasound. Int J Nanomed2020; 15: 3771–3790.
37.
BannuruRRNatovNSDasiUR, et al.Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis--meta-analysis. Osteoarthritis Cartilage2011; 19(6): 611–619.
38.
NoorNSKausNHMSzewczukMR, et al.Formulation, characterization and cytotoxicity effects of novel thymoquinone-PLGA-PF68 nanoparticles. Int J Mol Sci2021; 22(17): 9420.
39.
NguyenDWuJCorriganP, et al.Computational investigation on lipid bilayer disruption induced by amphiphilic Janus nanoparticles: combined effect of Janus balance and charged lipid concentration. Nanoscale2023; 15(39): 16112–16130.
